HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks
Atreca Inc (NASDAQ:BCEL) announced a licensing agreement with Zymeworks Inc (NYSE:ZYME) to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs). The agreement includes a two-year research term for Atreca to evaluate antibodies as ADCs using ZymeLink with the option for a third year. Atreca can acquire three commercial licenses to develop three unique…
Benzinga ·
Benzinga
